DUBLIN, Oct. 10, 2016 /PRNewswire/ -- Allergan
(NYSE: AGN) today announced that its data will be presented during
the 2016 American Academy of Ophthalmology (AAO) Annual Meeting in
Chicago, October 14-18.
Logo -
http://photos.prnewswire.com/prnh/20150612/222796LOGO
The scheduled times (noted in local Central Time) of the four
presentations and locations at McCormick Place are as follows:
Retina:
- Intravitreal Brimonidine Drug Delivery System (Brimonidine DDS)
in Patients with Geographic Atrophy: A Phase 2 Study
- Date and Time: Friday, October
14, 2016, 4:32 PM-4:37 PM
- Location: North Building, Hall B
- Presenter: William R.
Freeman, MD
- A Multicenter, Double Masked Phase 2 Clinical Trial Evaluating
Abicipar Pegol for Diabetic Macular Edema
- Date and Time: Saturday, October
15, 2016, 11:27 AM-11:32
AM
- Location: North Building, Hall B
- Presenter: Tarek S.
Hassan, MD
- Assessing the Association Between Duration of Edema and Visual
Acuity Outcomes in Diabetic Macular Edema: A Post-Hoc Analysis of
Protocol I
- Date and Time: Monday, October
17, 2016, 12:30 PM-2:00
PM
- Location: South Building, Hall A
- Presenter: Srinivas R. Sadda, MD
Glaucoma:
- Treatment of Newly Diagnosed Open-Angle Glaucoma Patients Over
a 4-Year Period: An Analysis of U.S. Claims Data
- Date and Time: Sunday, October
16, 2016, 12:30 PM-2:00
PM
- Location: South Building, Hall A
- Presenter: Gail F.
Schwartz, MD
About Allergan
Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global
pharmaceutical company and a leader in a new industry model –
Growth Pharma. Allergan is focused on developing,
manufacturing and commercializing branded pharmaceuticals, devices
and biologic products for patients around the world.
Allergan markets a portfolio of leading brands and best-in-class
products for the central nervous system, eye care, medical
aesthetics and dermatology, gastroenterology, women's health,
urology and anti-infective therapeutic categories.
Allergan is an industry leader in Open Science, the Company's
R&D model, which defines our approach to identifying and
developing game-changing ideas and innovation for better patient
care. This approach has led to Allergan building one of the
broadest development pipelines in the pharmaceutical industry with
65+ mid-to-late stage pipeline programs in development.
Our Company's success is powered by our more than 16,000 global
colleagues' commitment to being Bold for Life. Together, we build
bridges, power ideas, act fast and drive results for our customers
and patients around the world by always doing what is right.
With commercial operations in approximately 100 countries,
Allergan is committed to working with physicians, healthcare
providers and patients to deliver innovative and meaningful
treatments that help people around the world live longer, healthier
lives everyday.
For more information, visit Allergan's website at
www.Allergan.com.
Forward-Looking Statement
Statements contained in this press release that refer to future
events or other non-historical facts are forward-looking statements
that reflect Allergan's current perspective of existing trends and
information as of the date of this release. Except as expressly
required by law, Allergan disclaims any intent or obligation to
update these forward-looking statements. Actual results may differ
materially from Allergan's current expectations depending upon a
number of factors affecting Allergan's business. These factors
include, among others, the difficulty of predicting future clinical
results based on prior clinical results; the timing or outcome of
FDA approvals or actions, if any; the impact of competitive
products and pricing; market acceptance of and continued demand for
Allergan's products; difficulties or delays in manufacturing; the
ability of Allergan to complete the acquisition of Vitae
Pharmaceuticals, Inc.; and other risks and uncertainties detailed
in Allergan's periodic public filings with the Securities and
Exchange Commission, including but not limited to Allergan's Annual
Report on Form 10-K for the year ended December 31, 2015 and Quarterly Report on Form
10-Q for the quarter ended June 30,
2016 (certain of such periodic public filings having been
filed under the "Actavis plc" name). Except as expressly required
by law, Allergan disclaims any intent or obligation to update these
forward-looking statements.
CONTACTS:
Investors:
Lisa
DeFrancesco
(862) 261-7152
Media:
Mark Marmur
(973) 906-1526
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/allergan-to-showcase-novel-and-expanding-eye-care-portfolio-with-new-data-presentations-at-the-2016-american-academy-of-ophthalmology-annual-meeting-in-chicago-300341154.html
SOURCE Allergan plc